Secukinumab

CHEMBL1743068 Phase 4 Zugelassen Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Injected under the skin, this biologic targets a specific immune protein called interleukin-17A that plays a central role in the inflammation behind psoriasis, psoriatic arthritis, and ankylosing spondylitis. Patients often see significant skin clearance and reduced joint symptoms within a few weeks of starting treatment.

Therapeutische Bereiche

Rheumatoid Arthritis Asthma Melanoma Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Atopic Dermatitis Tuberculosis Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Injected under the skin, this biologic targets a specific immune protein called interleukin-17A that plays a central role in the inflammation behind psoriasis, psoriatic arthritis, and ankylosing spondylitis. Patients often see significant skin clearance and reduced joint symptoms within a few weeks of starting treatment.

Yes, Secukinumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743068. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Secukinumab auf PillFYI

Schnelldaten

Synonyme: 1

Externe Links

ChEMBL CHEMBL1743068

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.